Get started
Author

Christina Nowack

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2020 · George L. Bakris, Rajiv Agarwal, et al. · New England Journal of Medicine · 3,055
PDF
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
2021 · Rajiv Agarwal, Gerasimos Filippatos, et al. · European Heart Journal · 1,393
PDF
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
2015 · George L. Bakris, Rajiv Agarwal, et al. · JAMA · 719
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
2013 · Bertram Pitt, Lars Kober, et al. · European Heart Journal · 610
PDF
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
2016 · Gerasimos Filippatos, Stefan D. Anker, et al. · European Heart Journal · 451
PDF
Clinical Outcome Endpoints in Heart Failure Trials: A European Society of Cardiology Heart Failure Association Consensus Document
2013 · Faiez Zannad, Angeles Alonso Garcia, et al. · European Journal of Heart Failure · 236
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
2019 · Luis M. Ruilope, Rajiv Agarwal, et al. · American Journal of Nephrology · 215
PDF
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
2019 · George L. Bakris, Rajiv Agarwal, et al. · American Journal of Nephrology · 187
PDF
Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside
2016 · Peter Kolkhof, Frederic Jaisser, et al. · Handbook of experimental pharmacology · 183
A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy
2016 · Shigehiro Katayama, Daishiro Yamada, et al. · Journal of Diabetes and its Complications · 135
PDF
Nonsteroidal antagonists of the mineralocorticoid receptor
2015 · Peter Kolkhof, Christina Nowack, et al. · Current Opinion in Nephrology & Hypertension · 128
Cinaciguat, a Soluble Guanylate Cyclase Activator: Results from the Randomized, Controlled, Phase IIb COMPOSE Programme in Acute Heart Failure Syndromes
2012 · Mihai Gheorghiade, Stephen J. Greene, et al. · European Journal of Heart Failure · 125
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
2022 · Luis M. Ruilope, Rajiv Agarwal, et al. · Hypertension · 110
PDF
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
2022 · Rajiv Agarwal, Luis M. Ruilope, et al. · Journal of Hypertension · 105
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
2020 · Rajiv Agarwal, Stefan D Anker, et al. · Nephrology Dialysis Transplantation · 104
PDF
Rationale and Design of Mineralocorticoid Receptor Antagonist Tolerability Study-Heart Failure (ARTS-HF): A Randomized Study of Finerenone vs. Eplerenone in Patients who have Worsening Chronic Heart Failure with Diabetes and/or Chronic Kidney Disease
2015 · Bertram Pitt, Stefan D. Anker, et al. · European Journal of Heart Failure · 94
PDF
Rationale and Design of ARTS: A Randomized, Double-Blind Study of BAY 94-8862 in Patients with Chronic Heart Failure and Mild or Moderate Chronic Kidney Disease
2012 · Bertram Pitt, Gerasimos Filippatos, et al. · European Journal of Heart Failure · 92
PDF
A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease
2016 · Naoki Sato, Masayoshi Ajioka, et al. · Circulation Journal · 78
PDF
Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy
2014 · Luis M. Ruilope, Rajiv Agarwal, et al. · American Journal of Nephrology · 42
Masked and Nocturnal Hypertension in the ARTS-DN ABPM Sub-Study with Finerenone
2016 · L.M. Ruilope, C. Nowack, et al. · Journal of the American Society of Hypertension · 10
Treatment of acute decompensated heart failure with the soluble guanylate cyclase activator cinaciguat: The COMPOSE program – three randomized, controlled, phase IIb studies
2011 · Mihai Gheorghiade, Erland Erdmann, et al. · Journal of Cardiac Failure · 8
Safety Data and Beneficial Effects of the Combined Oral Contraceptive Ethinylestradiol 0.03 mg/Chlormadinone Acetate 2 mg (Belara®)
2010 · Daphnee S. Pushparajah, Petra Röhm, et al. · Clinical Drug Investigation · 8
Fc 090effects of Finerenone on Cardiorenal Outcomes in Blood Pressure Subgroups in Patients With Ckd and T2d
2021 · Luis Ruilope, Rajiv Agarwal, et al. · Nephrology Dialysis Transplantation · 4
Finerenone for Albuminuria in Patients With Diabetic Nephropathy—Reply
2016 · George L. Bakris, Christina Nowack · JAMA · 4
Pos-350 Finerenone in Mild to Severe Chronic Kidney Disease and Type 2 Diabetes: the Fidelity Prespecified Pooled Analysis
2022 · P. Rossing, R. Agarwal, et al. · Kidney International Reports · 1
Works count: 34
Citation count: 8,098
H-index: 19
I10-index: 20
Year
Topic
Type